Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised phase II trial to compare the toxicity, tolerability and activity of 2-drug combinations of nucleoside analogue reverse transcriptase inhibitors (NRTI's) lamivudine [(-)2'-deoxy-3'thiacytidine, 3tc], zidovudine (ZDV) and 1592U89 [abacavir]

Next Previous
X
Search
Trial Profile

A randomised phase II trial to compare the toxicity, tolerability and activity of 2-drug combinations of nucleoside analogue reverse transcriptase inhibitors (NRTI's) lamivudine [(-)2'-deoxy-3'thiacytidine, 3tc], zidovudine (ZDV) and 1592U89 [abacavir]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelfinavir (Primary) ; Abacavir; Lamivudine; Zidovudine
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms PENTA-5

    • Most Recent Events

    • 23 Jul 2009 Actual end date (31 Jul 1999) added as reported by ISRCTN: Current Controlled Trials.
    • 23 Jul 2009 Additional lead trial centres, planned patient number (120) and actual initiation date (23 Jan 1998) added as reported by ISRCTN: Current Controlled Trials.
    • 23 Jul 2009 Planned patient number (120) added as reported by ISRCTN: Current Controlled Trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top